GIUSEPPE DI BELLA > NEWS > null > null > La Somatostatina e Octreotide nelle malattie linfoproliferative

 
La Somatostatina e Octreotide nelle malattie linfoproliferative di S.I.B.O.R. - M.D.B.
 
 
Data: 14/07/2006
Tipologia: MDB - Documentazione
Lingua: Italiano
Anno: 2006
 
 
Descrizione:
PER LEGGERE E SCARICARE IL CAPITOLO SULLA SOMATOSTATINA E OCTREOTIDE, COMPLETO DI BIBLIOGRAFIA E RELATIVI ABSTRACT, CLICCARE QUESTO LINK.
Il file è di 80 pagine in formato PDF e pesa 557 kb.



BIBLIOGRAFIA





Adams, R. L., I. P. Adams, et al. (2005). "Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium." Br J Cancer 92(8): 1493-8.





Aguila, M. C., W. L. Dees, et al. (1991). "Evidence that somatostatin is localized and synthesized in lymphoid organs." Proc Natl Acad Sci U S A 88(24): 11485-9.





Boros, L. G., J. L. Brandes, et al. (1998). "Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin: a possible mechanism of antitumor action." Med Hypotheses 50(6): 501-6.





Brazeau, P., W. Vale, et al. (1973). "Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone." Science 179(68): 77-9.





Brevini-Gandolfi, T. A., F. Cillo, et al. (2001). "Somatostatin up-regulates topoisomerase II alpha expression and affects LNCaP cell cycle." Mol Cell Endocrinol 176(1-2): 103-10.





Cascinu, S., E. Del Ferro, et al. (1997). "Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients." Gastroenterology 113(3): 767-72.





Cattaneo, M. G., D. Amoroso, et al. (1996). "A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines." FEBS Lett 397(2-3): 164-8.





Cattaneo, M. G., G. Scita, et al. (1999). "Somatostatin inhibits PDGF-stimulated Ras activation in human neuroblastoma cells." FEBS Lett 459(1): 64-8.





Cattaneo, M. G., J. E. Taylor, et al. (2000). "Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells." FEBS Lett 481(3): 271-6.





Charland, S., M. J. Boucher, et al. (2001). "Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells." Endocrinology 142(1): 121-8.





Chen, X., Z. Liu, et al. (2001). "Antineoplastic mechanism of Octreotide action in human hepatoma." Chin Med J (Engl) 114(11): 1167-70.





Damge, C. and A. Hajri (1998). "Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma." Eur J Pharmacol 347(1): 77-86.





Danesi, R., C. Agen, et al. (1997). "Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995)." Clin Cancer Res 3(2): 265-72.





Danesi, R. and M. Del Tacca (1996). "The effects of the somatostatin analog octreotide on angiogenesis in vitro." Metabolism 45(8 Suppl 1): 49-50.





Dasgupta, P. (2004). "Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis." Pharmacol Ther 102(1): 61-85.





Dolan, J. T., D. M. Miltenburg, et al. (2001). "Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis." Ann Surg Oncol 8(3): 227-33.





Douziech, N., E. Calvo, et al. (1999). "Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1." Endocrinology 140(2): 765-77.





Feindt, J., R. Mentlein, et al. (1997). "Time-dependent influence of the somatostatin analogue octreotide on the proliferation of rat astrocytes and glioma cells." Brain Res 746(1-2): 309-13.





Ferjoux, G., C. Bousquet, et al. (2000). "Signal transduction of somatostatin receptors negatively controlling cell proliferation." J Physiol Paris 94(3-4): 205-10.





Ferone, D., P. M. van Hagen, et al. (1999). "Somatostatin receptors in the thymus." Ann Med 31 Suppl 2: 28-33.





Ferone, D., P. M. van Hagen, et al. (2004). "Somatostatin receptor distribution and function in immune system." Dig Liver Dis 36 Suppl 1: S68-77.





Florio, T., M. Morini, et al. (2003). "Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities." Endocrinology 144(4): 1574-84.





Garcia de la Torre, N., J. A. Wass, et al. (2002). "Antiangiogenic effects of somatostatin analogues." Clin Endocrinol (Oxf) 57(4): 425-41.





Giannetti, N., A. Enjalbert, et al. (2000). "Somatostatin analog SMS 201995 inhibits proliferation in human leukemia T-cell line: relevance of the adenylyl cyclase stimulation." J Cell Biochem 78(4): 666-73.





Harris, A. G. (1994). "Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects." Gut 35(3 Suppl): S1-4.





Held-Feindt, J., F. Forstreuter, et al. (2001). "Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells." Brain Res Mol Brain Res 87(1): 12-21.





Held-Feindt, J., B. Krisch, et al. (2000). "Somatostatin receptors in gliomas." J Physiol Paris 94(3-4): 251-8.





Held-Feindt, J., B. Krisch, et al. (1999). "Molecular analysis of the somatostatin receptor subtype 2 in human glioma cells." Brain Res Mol Brain Res 64(1): 101-7.





Ishihara, S., S. Hassan, et al. (1999). "Growth inhibitory effects of somatostatin on human leukemia cell lines mediated by somatostatin receptor subtype 1." Peptides 20(3): 313-8.





Jeay, S., G. E. Sonenshein, et al. (2002). "Growth hormone can act as a cytokine controlling survival and proliferation of immune cells: new insights into signaling pathways." Mol Cell Endocrinol 188(1-2): 1-7.





Kouroumalis, E., P. Skordilis, et al. (1998). "Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study." Gut 42(3): 442-7.





Kouroumalis, E. A. (2001). "Octreotide for cancer of the liver and biliary tree." Chemotherapy 47 Suppl 2: 150-61.





Lahlou, H., J. Guillermet, et al. (2004). "Molecular signaling of somatostatin receptors." Ann N Y Acad Sci 1014: 121-31.





Lawnicka, H., H. Stepien, et al. (2000). "Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture." Biochem Biophys Res Commun 268(2): 567-71.





Lugtenburg, P. J., E. P. Krenning, et al. (2001). "Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease: more extended disease identified." Br J Haematol 112(4): 936-44.





Magnavita, N., L. Teofili, et al. (1996). "Hodgkin's lymphoma in a cyclist treated with growth hormone." Am J Hematol 52(1): 65-6.





Melen-Mucha, G., K. Winczyk, et al. (1998). "Somatostatin analogue octreotide and melatonin inhibit bromodeoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplantable murine colon 38 cancer." Anticancer Res 18(5A): 3615-9.





Mishima, M., T. Yano, et al. (1999). "Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160." Am J Obstet Gynecol 181(3): 583-90.





Nakamura, H., T. Koike, et al. (1987). "Identification of lymphoid cell lines bearing receptors for somatostatin." Immunology 62(4): 655-8.





Olias, G., C. Viollet, et al. (2004). "Regulation and function of somatostatin receptors." J Neurochem 89(5): 1057-91.





Patel, P. C., R. Barrie, et al. (1994). "Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis." Surgery 116(6): 1148-52.





Raderer, M., M. H. Hejna, et al. (1999). "Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide." Am J Gastroenterol 94(1): 278-9.





Raderer, M., M. H. Hejna, et al. (2000). "Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo." Int J Oncol 16(6): 1197-201.





Robbins, R. J. (1996). "Somatostatin and cancer." Metabolism 45(8 Suppl 1): 98-100.





Rogers, P. C., D. Komp, et al. (1977). "Possible effects of growth hormone on development of acute lymphoblastic leukaemia." Lancet 2(8035): 434-5.





Szende, B., A. Horvath, et al. (2003). "Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma." Br J Cancer 88(1): 132-6.





Szepeshazi, K., G. Halmos, et al. (1999). "Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs." J Cancer Res Clin Oncol 125(8-9): 444-52.





Szepeshazi, K., A. V. Schally, et al. (2002). "Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status." Cancer Res 62(3): 781-8.





Szereday, Z., A. V. Schally, et al. (2003). "Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238." Int J Oncol 22(5): 1141-6.





Tejeda, M., D. Gaal, et al. (2003). "The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts." Anticancer Res 23(5A): 4061-6.





Tejeda, M., D. Gaal, et al. (2005). "Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models." Anticancer Res 25(1A): 325-30.





Tesei, A., L. Ricotti, et al. (2000). "Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study." J Chemother 12(5): 421-30.





Todisco, M., P. Casaccia, et al. (2001). "Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's lymphomas at advanced stage: results of a phase II trial." Cancer Biother Radiopharm 16(2): 171-7.





Tompa, A., M. G. Jakab, et al. (2000). "The somatostatin analogue peptide TT-232 induces apoptosis and chromosome breakage in cultured human lymphocytes." Mutat Res 465(1-2): 61-8.





Tsutsumi, A., H. Takano, et al. (1997). "Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells." Cell Immunol 181(1): 44-9.





van den Anker-Lugtenburg, P. J., F. Heule, et al. (1996). "Somatostatin receptor scintigraphy in cutaneous malignant lymphomas." J Am Acad Dermatol 34(6): 985-93.





van den Anker-Lugtenburg, P. J., B. Lowenberg, et al. (1996). "The relevance of somatostatin receptor expression in malignant lymphomas." Metabolism 45(8 Suppl 1): 96-7.





Weckbecker, G., F. Raulf, et al. (1993). "Somatostatin analogs for diagnosis and treatment of cancer." Pharmacol Ther 60(2): 245-64.





Witzig, T. E., L. Letendre, et al. (1995). "Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial." J Clin Oncol 13(8): 2012-5.





Woltering, E. A. (2003). "Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives." Cancer Biother Radiopharm 18(4): 601-9.





Yano, T., S. Radulovic, et al. (2000). "Inhibition of human epithelial ovarian cancer cell growth in vitro by somatostatin analog RC-160." Oncology 59 Suppl 1: 45-9.





Zalatnai, A. (1999). "Epidermal growth factor receptor, somatostatin and bcl-2 in human pancreatic tumor xenografts. An immunohistochemical study." Pathol Oncol Res 5(2): 146-51.

 
 
 

PER LEGGERE E SCARICARE IL CAPITOLO SULLA SOMATOSTATINA E OCTREOTIDE, COMPLETO DI BIBLIOGRAFIA E RELATIVI ABSTRACT, CLICCARE QUESTO LINK.
Il file è di 80 pagine in formato PDF e pesa 557 kb.



BIBLIOGRAFIA





Adams, R. L., I. P. Adams, et al. (2005). "Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium." Br J Cancer 92(8): 1493-8.





Aguila, M. C., W. L. Dees, et al. (1991). "Evidence that somatostatin is localized and synthesized in lymphoid organs." Proc Natl Acad Sci U S A 88(24): 11485-9.





Boros, L. G., J. L. Brandes, et al. (1998). "Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin: a possible mechanism of antitumor action." Med Hypotheses 50(6): 501-6.





Brazeau, P., W. Vale, et al. (1973). "Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone." Science 179(68): 77-9.





Brevini-Gandolfi, T. A., F. Cillo, et al. (2001). "Somatostatin up-regulates topoisomerase II alpha expression and affects LNCaP cell cycle." Mol Cell Endocrinol 176(1-2): 103-10.





Cascinu, S., E. Del Ferro, et al. (1997). "Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients." Gastroenterology 113(3): 767-72.





Cattaneo, M. G., D. Amoroso, et al. (1996). "A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines." FEBS Lett 397(2-3): 164-8.





Cattaneo, M. G., G. Scita, et al. (1999). "Somatostatin inhibits PDGF-stimulated Ras activation in human neuroblastoma cells." FEBS Lett 459(1): 64-8.





Cattaneo, M. G., J. E. Taylor, et al. (2000). "Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells." FEBS Lett 481(3): 271-6.





Charland, S., M. J. Boucher, et al. (2001). "Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells." Endocrinology 142(1): 121-8.





Chen, X., Z. Liu, et al. (2001). "Antineoplastic mechanism of Octreotide action in human hepatoma." Chin Med J (Engl) 114(11): 1167-70.





Damge, C. and A. Hajri (1998). "Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma." Eur J Pharmacol 347(1): 77-86.





Danesi, R., C. Agen, et al. (1997). "Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995)." Clin Cancer Res 3(2): 265-72.





Danesi, R. and M. Del Tacca (1996). "The effects of the somatostatin analog octreotide on angiogenesis in vitro." Metabolism 45(8 Suppl 1): 49-50.





Dasgupta, P. (2004). "Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis." Pharmacol Ther 102(1): 61-85.





Dolan, J. T., D. M. Miltenburg, et al. (2001). "Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis." Ann Surg Oncol 8(3): 227-33.





Douziech, N., E. Calvo, et al. (1999). "Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1." Endocrinology 140(2): 765-77.





Feindt, J., R. Mentlein, et al. (1997). "Time-dependent influence of the somatostatin analogue octreotide on the proliferation of rat astrocytes and glioma cells." Brain Res 746(1-2): 309-13.





Ferjoux, G., C. Bousquet, et al. (2000). "Signal transduction of somatostatin receptors negatively controlling cell proliferation." J Physiol Paris 94(3-4): 205-10.





Ferone, D., P. M. van Hagen, et al. (1999). "Somatostatin receptors in the thymus." Ann Med 31 Suppl 2: 28-33.





Ferone, D., P. M. van Hagen, et al. (2004). "Somatostatin receptor distribution and function in immune system." Dig Liver Dis 36 Suppl 1: S68-77.





Florio, T., M. Morini, et al. (2003). "Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities." Endocrinology 144(4): 1574-84.





Garcia de la Torre, N., J. A. Wass, et al. (2002). "Antiangiogenic effects of somatostatin analogues." Clin Endocrinol (Oxf) 57(4): 425-41.





Giannetti, N., A. Enjalbert, et al. (2000). "Somatostatin analog SMS 201995 inhibits proliferation in human leukemia T-cell line: relevance of the adenylyl cyclase stimulation." J Cell Biochem 78(4): 666-73.





Harris, A. G. (1994). "Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects." Gut 35(3 Suppl): S1-4.





Held-Feindt, J., F. Forstreuter, et al. (2001). "Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells." Brain Res Mol Brain Res 87(1): 12-21.





Held-Feindt, J., B. Krisch, et al. (2000). "Somatostatin receptors in gliomas." J Physiol Paris 94(3-4): 251-8.





Held-Feindt, J., B. Krisch, et al. (1999). "Molecular analysis of the somatostatin receptor subtype 2 in human glioma cells." Brain Res Mol Brain Res 64(1): 101-7.





Ishihara, S., S. Hassan, et al. (1999). "Growth inhibitory effects of somatostatin on human leukemia cell lines mediated by somatostatin receptor subtype 1." Peptides 20(3): 313-8.





Jeay, S., G. E. Sonenshein, et al. (2002). "Growth hormone can act as a cytokine controlling survival and proliferation of immune cells: new insights into signaling pathways." Mol Cell Endocrinol 188(1-2): 1-7.





Kouroumalis, E., P. Skordilis, et al. (1998). "Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study." Gut 42(3): 442-7.





Kouroumalis, E. A. (2001). "Octreotide for cancer of the liver and biliary tree." Chemotherapy 47 Suppl 2: 150-61.





Lahlou, H., J. Guillermet, et al. (2004). "Molecular signaling of somatostatin receptors." Ann N Y Acad Sci 1014: 121-31.





Lawnicka, H., H. Stepien, et al. (2000). "Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture." Biochem Biophys Res Commun 268(2): 567-71.





Lugtenburg, P. J., E. P. Krenning, et al. (2001). "Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease: more extended disease identified." Br J Haematol 112(4): 936-44.





Magnavita, N., L. Teofili, et al. (1996). "Hodgkin's lymphoma in a cyclist treated with growth hormone." Am J Hematol 52(1): 65-6.





Melen-Mucha, G., K. Winczyk, et al. (1998). "Somatostatin analogue octreotide and melatonin inhibit bromodeoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplantable murine colon 38 cancer." Anticancer Res 18(5A): 3615-9.





Mishima, M., T. Yano, et al. (1999). "Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160." Am J Obstet Gynecol 181(3): 583-90.





Nakamura, H., T. Koike, et al. (1987). "Identification of lymphoid cell lines bearing receptors for somatostatin." Immunology 62(4): 655-8.





Olias, G., C. Viollet, et al. (2004). "Regulation and function of somatostatin receptors." J Neurochem 89(5): 1057-91.





Patel, P. C., R. Barrie, et al. (1994). "Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis." Surgery 116(6): 1148-52.





Raderer, M., M. H. Hejna, et al. (1999). "Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide." Am J Gastroenterol 94(1): 278-9.





Raderer, M., M. H. Hejna, et al. (2000). "Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo." Int J Oncol 16(6): 1197-201.





Robbins, R. J. (1996). "Somatostatin and cancer." Metabolism 45(8 Suppl 1): 98-100.





Rogers, P. C., D. Komp, et al. (1977). "Possible effects of growth hormone on development of acute lymphoblastic leukaemia." Lancet 2(8035): 434-5.





Szende, B., A. Horvath, et al. (2003). "Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma." Br J Cancer 88(1): 132-6.





Szepeshazi, K., G. Halmos, et al. (1999). "Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs." J Cancer Res Clin Oncol 125(8-9): 444-52.





Szepeshazi, K., A. V. Schally, et al. (2002). "Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status." Cancer Res 62(3): 781-8.





Szereday, Z., A. V. Schally, et al. (2003). "Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238." Int J Oncol 22(5): 1141-6.





Tejeda, M., D. Gaal, et al. (2003). "The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts." Anticancer Res 23(5A): 4061-6.





Tejeda, M., D. Gaal, et al. (2005). "Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models." Anticancer Res 25(1A): 325-30.





Tesei, A., L. Ricotti, et al. (2000). "Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study." J Chemother 12(5): 421-30.





Todisco, M., P. Casaccia, et al. (2001). "Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's lymphomas at advanced stage: results of a phase II trial." Cancer Biother Radiopharm 16(2): 171-7.





Tompa, A., M. G. Jakab, et al. (2000). "The somatostatin analogue peptide TT-232 induces apoptosis and chromosome breakage in cultured human lymphocytes." Mutat Res 465(1-2): 61-8.





Tsutsumi, A., H. Takano, et al. (1997). "Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells." Cell Immunol 181(1): 44-9.





van den Anker-Lugtenburg, P. J., F. Heule, et al. (1996). "Somatostatin receptor scintigraphy in cutaneous malignant lymphomas." J Am Acad Dermatol 34(6): 985-93.





van den Anker-Lugtenburg, P. J., B. Lowenberg, et al. (1996). "The relevance of somatostatin receptor expression in malignant lymphomas." Metabolism 45(8 Suppl 1): 96-7.





Weckbecker, G., F. Raulf, et al. (1993). "Somatostatin analogs for diagnosis and treatment of cancer." Pharmacol Ther 60(2): 245-64.





Witzig, T. E., L. Letendre, et al. (1995). "Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial." J Clin Oncol 13(8): 2012-5.





Woltering, E. A. (2003). "Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives." Cancer Biother Radiopharm 18(4): 601-9.





Yano, T., S. Radulovic, et al. (2000). "Inhibition of human epithelial ovarian cancer cell growth in vitro by somatostatin analog RC-160." Oncology 59 Suppl 1: 45-9.





Zalatnai, A. (1999). "Epidermal growth factor receptor, somatostatin and bcl-2 in human pancreatic tumor xenografts. An immunohistochemical study." Pathol Oncol Res 5(2): 146-51.

 
 
 

 

Documento Allegato

Stampa